It is common for the medical fraternity to discover adverse pharmacoviiglance for medicines. Further, drugs and medications meant to control a particular disease may trigger other health problems. For this reason, it is important for the pharmaceutical industry to stay wary of the side-effects of medications.
Pharmaceutical companies have often intimated the Food and Drug Administration (FDA) about the toxicity of multiple medications. In a similar instance, an online pharma company, Valisure, has pointed to the cancer-inducing properties of valsartan. It is a medication to control blood pressure, and it contains heavy amount of dimethylformamide. Novartis is one of the several drug manufacturers who sell valsartan under their name. Valisure claimed that the presence of dimethylformamide in the drug is responsible for its cancer-causing action.
Use of Valsartan
Doctors prescribe valsartan for adults to control and manage hypertension. On the other hand, the medical fraternity has discussed the ill-effects of dimethylformamide. According to the World Health Organization (WHO), dimethylformamide could act as a human carcinogen. Valisure urged the FDA to review the action of dimethylformamide and impose limits on its intake. Further, Valisure stated that it knew of five pharma companies that produced valsartan.
FDA’s Take on New Claims
One of FDA’s spokespersons assured that the administration will investigate and evaluate Valisure’s claims. Meanwhile, the FDA also advised patients to continue with their regular blood pressure medications until further recourse. The administration suggested that the patients should not discontinue intake even after the medicine is recalled. Consequently, this could adversely impact health of patients who have used valsartan for years.